Normalizing ELISPOT responses to T-cell counts: A novel approach for quantification of HCMV-specific CD4+ and CD8+ T-cell responses in kidney transplant recipients

Journal of Clinical Virology

Volumn 61, Issue 1, 2014, Pages 65-73

  Calarota, Sandra A ^a   Chiesa, Antonella ^a   Scaramuzzi, Lucia ^a   Adzasehoun, Kodjo M G ^a   Comolli, Giuditta ^a   Mangione, Filippo ^a   Esposito, Pasquale ^a   Baldanti, Fausto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

ELISPOT; Human cytomegalovirus; Interferon ; Kidney transplantation; T cell counts

Indexed keywords

BASILIXIMAB; CD56 ANTIGEN; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOPROTEIN; PHOSPHOPROTEIN 65; SYNTHETIC PEPTIDE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; GAMMA INTERFERON; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY GRAFT; LIMIT OF QUANTITATION; MALE; MICROPLATE READER; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRAL DISEASE IMMUNOFLUORESCENCE ASSAY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; SECRETION (PROCESS); STANDARDS;

ADULT; AGED; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; TRANSPLANT RECIPIENTS;

EID: 84905123085     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.05.017     Document Type: Article

References (36)

1. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22(1):76-98.
2. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007, 357(25):2601-2614.
3. Humar A., Snydman D. AST Infectious Diseases Community of Practice Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009, 9(Suppl. 4):S78-S86.
4. Kotton C.N. CMV: prevention, diagnosis and therapy. Am J Transplant 2013, 13(Suppl. 3):24-40.
5. Egli A., Humar A., Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012, 55(12):1678-1689.
6. Lozza L., Lilleri D., Percivalle E., Fornara C., Comolli G., Revello M.G., et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005, 35(6):1795-1804.
7. Gerna G., Lilleri D., Fornara C., Comolli G., Lozza L., Campana C., et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006, 6(10):2356-2364.
8. Gerna G., Lilleri D., Chiesa A., Zelini P., Furione M., Comolli G., et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011, 11(11):2463-2471.
9. Godard B., Gazagne A., Gey A., Baptiste M., Vingert B., Pegaz-Fiornet B., et al. Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Hum Immunol 2004, 65(11):1307-1318.
10. Nickel P., Bold G., Presber F., Biti D., Babel N., Kreutzer S., et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol 2009, 20(4):238-242.
11. Abate D., Saldan A., Fiscon M., Cofano S., Paciolla A., Furian L., et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010, 202(4):585-594.
12. Kiecker F., Streitz M., Ay B., Cherepnev G., Volk H.D., Volkmer-Engert R., et al. Analysis of antigen-specific T-cell responses with synthetic peptides - what kind of peptide for which purpose?. Hum Immunol 2004, 65(5):523-536.
13. Draenert R., Altfeld M., Brander C., Basgoz N., Corcoran C., Wurcel A.G., et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 2003, 275(1-2):19-29.
14. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001, 255(1-2):27-40.
15. Gerna G., Baldanti F., Torsellini M., Minoli L., Viganò M., Oggionnis T., et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antivir Ther 2007, 12(1):63-72.
16. Walker S., Fazou C., Crough T., Holdsworth R., Kiely P., Veale M., et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007, 9(2):165-170.
17. Calarota S.A., Chiesa A., Zelini P., Comolli G., Minoli L., Baldanti F. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay. Immunology 2013, 139(4):533-544.
18. Calarota S.A., Zelini P., De Silvestri A., Chiesa A., Comolli G., Sarchi E., et al. Kinetics of T-lymphocyte subsets and posttransplant opportunistic infections in heart and kidney transplant recipients. Transplantation 2012, 93(1):112-119.
19. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996, 70(11):7569-7579.
20. Kern F., Surel I.P., Faulhaber N., Frömmel C., Schneider-Mergener J., Schönemann C., et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999, 73(10):8179-8184.
21. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994, 43(1):103-110.
22. Kern F., Faulhaber N., Frömmel C., Khatamzas E., Prösch S., Schönemann C., et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000, 30(6):1676-1682.
23. Slezak S.L., Bettinotti M., Selleri S., Adams S., Marincola F.M., Stroncek D.F. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med 2007, 5:17.
24. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202(5):673-685.
25. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003, 77(9):5226-5240.
26. Sinclair J., Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006, 87(Pt 7):1763-1779.
27. van Zanten J., Harmsen M.C., van der Meer P., van der Bij W., van Son W.J., van der Giessen M., et al. Proliferative T cell responses to four human cytomegalovirus-specific proteins in healthy subjects and solid organ transplant recipients. J Infect Dis 1995, 172(3):879-882.
28. He H., Rinaldo C.R., Morel P.A. T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development. J Gen Virol 1995, 76(Pt 7):1603-1610.
29. Lilleri D., Zelini P., Fornara C., Comolli G., Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007, 7(8):1997-2005.
30. Zelini P., Lilleri D., Comolli G., Rognoni V., Chiesa A., Fornara C., et al. Human cytomegalovirus-specific CD4(+) and CD8(+) T-cell response determination: comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host. Clin Immunol 2010, 136(2):269-281.
31. Torti N., Oxenius A. T cell memory in the context of persistent herpes viral infections. Viruses 2012, 4(7):1116-1143.
32. Mattes F.M., Vargas A., Kopycinski J., Hainsworth E.G., Sweny P., Nebbia G., et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008, 8(5):990-999.
33. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005, 201(7):1031-1036.
34. Sester M., Sester U., Gärtner B., Heine G., Girndt M., Mueller-Lantzsch N., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001, 71(9):1287-1294.
35. Egli A., Binet I., Binggeli S., Jäger C., Dumoulin A., Schaub S., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008, 6:29.
36. Sund F., Lidehäll A.K., Claesson K., Foss A., Tötterman T.H., Korsgren O., et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant 2010, 24(3):401-409.